# NTLA — replay s8 — bf16

## Metadata

ticker: NTLA
arm: bf16
sample: 8
served_name: financial-lora
source_findings: eval/runs/raw/v924f-findings/NTLA_local-model.md
context_sha256: 6761526dd59ed3e0a82dedfba025f89cfd45cbb4531936090ddc926547b4f182
agent_core_sha256: f45e278f9722d5c331843a77692b154904f72edd059e6a3da48976a7945db44e
sampling: {"temperature": 0.1, "max_tokens": 512, "top_p": 0.8, "top_k": 20, "repetition_penalty": 1.1, "min_p": 0.0}
endpoint: http://localhost:30880
generated_utc: 2026-09-30T04:48:58Z
financial_health_prompt_sha256: 1d02c948fb5c1fc71807061e07b4b455bdfaf9aea4915e2bbba55c411ccedb9f
financial_health_seed: 1080180
financial_health_response_model: financial-lora
financial_health_finish_reason: stop
financial_health_completion_tokens: 152
risk_factors_prompt_sha256: fc6b632fba61396dfab174244992575c847ac744d384865929688e3c64c47f72
risk_factors_seed: 1080181
risk_factors_response_model: financial-lora
risk_factors_finish_reason: stop
risk_factors_completion_tokens: 321

## Stock data

{
  "ticker": "NTLA",
  "company_name": "Intellia Therapeutics, Inc.",
  "current_price": 12.33,
  "currency": "USD",
  "market_cap": 1727762048.0,
  "forward_pe": -4.7440777,
  "week_52_high": 28.25,
  "week_52_low": 7.95,
  "revenue": 59506000.0,
  "net_income": -399975008.0,
  "profit_margin": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

<!-- replay-section: Financial Health -->
### Financial Health

Intellia Therapeutics, Inc., trades under the ticker symbol NTLA. It is classified as a healthcare company within the biotechnology sector. As of February 26, 2026, the company's current share price stands at $12.33 per share in the United States. The company carries a market capitalization of $172.8 billion, which represents approximately 1.2% of the total U.S. equity market capitalization. As of August 6, 2026, the company reports net income of -$39.9 billion, a significant negative net income of -$39.9 billion. This indicates a substantial loss over the reporting period.

<!-- replay-section: Risk Factors -->
### Primary Risk Factors Disclosed

#### Clinical Development and Regulatory Risks
- CRISPR genome editing technology has only recently been clinically validated for human therapeutic use, and in vivo CRISPR-based therapies remain largely unproven.
- No genome editing in vivo therapy has been approved in the U.S., EU, or other key jurisdictions.
- Clinical development is lengthy, expensive, and uncertain in outcome.
- Regulatory agencies have very limited or no experience with CRISPR-based therapeutics, which may require additional testing and delay development.
- The company faces challenges in obtaining regulatory authorization and approval for clinical trials.

#### Technical and Development Challenges
- Successfully developing safe delivery methods to target cells and optimizing efficacy and specificity remain unsolved issues.
- Manufacturing, scalability, and profitability of CRISPR products are uncertain.
- Success in one CRISPR product does not guarantee success in others.
- Clinical trials may fail to demonstrate safety or efficacy, or produce negative or inconclusive results.

#### Market Adoption and Perception Risks
- Public perception and media coverage of safety or efficacy issues may discourage clinical trial participation and patient/physician acceptance.
- Ethical concerns related to genome editing may adversely influence adoption.
- Physicians and healthcare providers are often slow to adopt new technologies and may view these therapies as too complex or risky.
- Healthcare providers and payors may determine that benefits do not outweigh costs.

#### Operational Risks
- Challenges in patient enrollment, retention, and follow-up.
- Supply chain and manufacturing challenges for materials and product candidates.
- Dependence on third-party contractors and clinical trial sites.
